Vinflunine is an investigational drug.
There have been 34 clinical trials for Vinflunine.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 13th 2015.
The most common disease conditions in clinical trials are Carcinoma, Transitional Cell, Carcinoma, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are Bristol-Myers Squibb, Pierre Fabre Medicament, and SCRI Development Innovations, LLC.
There is one US patent protecting this investigational drug and fifteen international patents.